+5,267.8%
NKE vs GSK
+1,644.3%
+3,623.5%
-79.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.1% | -0.1% | -4.0% | -4.1% |
| 7D | -13.3% | -5.3% | -8.0% | -11.8% |
| 30D | -12.3% | -3.7% | -8.6% | -11.1% |
| 3M | -17.3% | -7.3% | -10.0% | -15.2% |
| 6M | -24.0% | -4.2% | -19.8% | -23.1% |
| YTD | -47.0% | +0.9% | -47.8% | -47.4% |
| 1Y | -44.6% | +7.3% | -51.9% | -46.2% |
| 3Y | -66.8% | +52.7% | -119.5% | -71.8% |
| 5Y | -79.4% | +40.1% | -119.5% | -82.2% |
| 10Y | -25.5% | +98.7% | -124.2% | -43.0% |
| All | +5,267.8% | +1,644.3% | +3,623.5% | +1,663.2% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling